A separate study127 included 7 children with r/r AML and administered one of two different CLL1-directed CAR T-cell therapies, either a 4-1BB-based costimulatory approach (3 patients), or a CD28/CD27-based costimulatory construct (4 patients). The gene discussed is CLEC12A; the disease is acute myeloid leukemia.